The Volatile Journey of Apollomics Inc Stock
Apollomics Inc. (NASDAQ:) has been experiencing significant volatility in its stock, with a drop of over 75% in the last month. Let’s delve deeper into what’s been happening:
What To Know:
On Thursday, Apollomics announced a report by the Veneto Institute of Oncology regarding the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion.
The report revealed that the patient showed an impressive Partial Response (PR) after 8 weeks of treatment with vebreltinib monotherapy during their participation in the SPARTA study.
Additionally, Apollomics announced the upcoming presentation of vebreltinib’s efficacy and safety data from the KUNPENG clinical trial on Monday.
“The clinical results demonstrate the potential of vebreltinib as a new treatment for patients with cancers driven by MET alterations, particularly in Non-Small Cell Lung Cancer (NSCLC) with MetEx14 skipping mutation,” said Guo-Liang Yu, Ph.D., CEO of Apollomics.
Furthermore, vebreltinib is also showing progress in clinical programs for patients with various MET alterations.
These announcements have resulted in a surge in trading volume for Apollomics Inc. As of Friday, more than 67 million shares have already been traded, surpassing the stock’s 100-day average volume of less than 53 thousand shares.
Related News: Why Mullen Automotive Stock Is Charging Higher
APLM Price Action:
According to data from Benzinga Pro, Apollomics Inc. shares are currently up 51% at 86 cents.
Image: Phoenix Locklear from Pixabay
Keywords: Apollomics Inc stock, volatility, vebreltinib, GBM with PTPRZ-MET fusion, SPARTA study, KUNPENG clinical trial, MET alterations, Non-Small Cell Lung Cancer (NSCLC), MetEx14 skipping mutation